ArticlePloS one2014
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.The Cochrane database of systematic reviews · 2016Pooled it
- Medical interventions for high-grade vulval intraepithelial neoplasia.The Cochrane database of systematic reviews · 2015Pooled it
- Survival and prognostic factors in vaginal cancer: an analysis of 2016-2020 nationwide data.International journal of clinical oncology · 2026Observational
- Review
- Decoding impact of human papillomavirus in gynecological oncology: a narrative review.Obstetrics & gynecology science · 2025Article
- Spectrum of gynecologic malignancies in Northeastern Nigeria.Frontiers in oncology · 2025Article
- HPV-Related Cancers in Bosnia and Herzegovina: A Comprehensive Review.Acta medica academica · 2024Review
- 5-aminolevulinic acid induced photodynamic reactions in diagnosis and therapy for female lower genital tract diseases.Frontiers in medicine · 2024Review
- Heat maps present the spatial distribution of human papillomavirus infection in Zhejiang Province, China.Oncology letters · 2021Article
- Mapping evidence on ovarian, endometrial, vaginal, and vulva cancer research in Africa: a scoping review protocol.Systematic reviews · 2021Article
- Human papillomavirus genotype-specific risks for cervical intraepithelial lesions.Human vaccines & immunotherapeutics · 2021Article
- The role and utility of population-based cancer registries in cervical cancer surveillance and control.Preventive medicine · 2021Article
- Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.International journal of cancer · 2019Article
- Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark - the SHADE.BMC infectious diseases · 2019Observational
- Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention.Cancer medicine · 2019Article
- Hospitalization burden associated with malignant neoplasia and in situ carcinoma in vulva and vagina during a 5-year period (2009-2013) in Spain: An epidemiological study.Papillomavirus research (Amsterdam, Netherlands) · 2018Observational
- Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine.Infectious agents and cancer · 2018Article
- Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population.Frontiers in microbiology · 2018Article
- Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.Papillomavirus research (Amsterdam, Netherlands) · 2016Article
- Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark - the SHADE.BMC cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfection with high-risk human papillomavirus (HPV) is causally related to cervical, vulvar and vaginal pre-invasive neoplasias and cancers. Highly effective vaccines against HPV types 16/18 have been available since 2006, and are currently used in many countries in combination with cervical cancer screening to control the burden of cervical cancer. We estimated the overall and age-specific incidence rate (IR) of cervical, vulvar and vaginal cancer and pre-invasive neoplasia in Denmark, Iceland, Norway and Sweden in 2004-2006, prior to the availability of HPV vaccines, in order to establish a baseline for surveillance. We also estimated the population attributable fraction to determine roughly the expected effect of HPV16/18 vaccination on the incidence of these diseases.
methodsInformation on incident cervical, vulvar and vaginal cancers and high-grade pre-invasive neoplasias was obtained from high-quality national population-based registries. A literature review was conducted to define the fraction of these lesions attributable to HPV16/18, i.e., those that could be prevented by HPV vaccination.
resultsAmong the four countries, the age-standardised IR/10⁵ of cervical, vaginal and vulvar cancer ranged from 8.4-13.8, 1.3-3.1 and 0.2-0.6, respectively. The risk for cervical cancer was highest in women aged 30-39, while vulvar and vaginal cancers were most common in women aged 70+. Age-standardised IR/10⁵ of cervical, vulvar and vaginal pre-invasive neoplasia ranged between 138.8-183.2, 2.5-8.8 and 0.5-1.3, respectively. Women aged 20-29 had the highest risk for cervical pre-invasive neoplasia, while vulvar and vaginal pre-invasive neoplasia peaked in women aged 40-49 and 60-69, respectively. Over 50% of the observed 47,820 incident invasive and pre-invasive cancer cases in 2004-2006 can be attributed to HPV16/18.
conclusionIn the four countries, vaccination against HPV 16/18 could prevent approximately 8500 cases of gynecological cancer and pre-cancer annually. Population-based cancer and vaccination registries are essential to assess the predicted public health effects of HPV vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.